{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:43:20Z","timestamp":1762821800749,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.retram.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T09:01:48Z","timestamp":1593507708000},"page":"131-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status"],"prefix":"10.1016","volume":"68","author":[{"given":"Moussab","family":"Damlaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bader","family":"Alahmari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Alaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameera","family":"Johani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"AlSaedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Bosaeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Al-Zahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.retram.2020.04.005_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/infdis\/jir722","article-title":"Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission","volume":"205","author":"Stowell","year":"2012","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.retram.2020.04.005_bib0010","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/CMR.00015-13","article-title":"Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation","volume":"26","author":"Razonable","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.retram.2020.04.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26639","article-title":"Cytomegalovirus reactivation posthematopoietic stem cell transplantation (HSCT) and type of graft: a step toward rationalizing CMV testing and positively impacting the economics of HSCT in developing countries","volume":"64","author":"Uppuluri","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0020","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"issue":"10","key":"10.1016\/j.retram.2020.04.005_bib0025","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx143","article-title":"Comparison of standardized cytomegalovirus (CMV) viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease","volume":"4","author":"Dioverti","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.retram.2020.04.005_bib0035","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V86.7.2815.2815","article-title":"Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation","volume":"86","author":"Einsele","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan","year":"2017","journal-title":"Blood Rev"},{"issue":"25","key":"10.1016\/j.retram.2020.04.005_bib0055","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2020.04.005_bib0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcv.2015.06.006","article-title":"Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients","volume":"69","author":"Tan","year":"2015","journal-title":"J Clin Virol"},{"issue":"11","key":"10.1016\/j.retram.2020.04.005_bib0065","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Trans"},{"issue":"1","key":"10.1016\/j.retram.2020.04.005_bib0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.retram.2020.04.005_bib0075","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2020.04.005_bib0080","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Trans"},{"issue":"12","key":"10.1016\/j.retram.2020.04.005_bib0085","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood and marrow Trans: J Am Soc Blood and Marrow Trans"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0090","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software\u2019 EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2020.04.005_bib0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"10.1016\/j.retram.2020.04.005_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ebiom.2015.05.003","article-title":"Clinical application of variation in replication kinetics during episodes of post-transplant cytomegalovirus infections","volume":"2","author":"Lodding","year":"2015","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.retram.2020.04.005_bib0105","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2020.04.005_bib0110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","article-title":"Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients","volume":"24","author":"Camargo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.retram.2020.04.005_bib0115","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2020.04.005_bib0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","article-title":"Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia","volume":"128","author":"Elmaagacli","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2020.04.005_bib0125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2015.09.006","article-title":"Effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic stem cell transplantation in pediatric acute leukemia","volume":"22","author":"Inagaki","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.retram.2020.04.005_bib0130","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:38:53Z","timestamp":1762821533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318620300337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S2452318620300337"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2020.04.005","relation":{},"ISSN":["2452-3186"],"issn-type":[{"type":"print","value":"2452-3186"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}